 Connection
Steven Bair to Drug Resistance, Neoplasm
This is a "connection" page, showing publications Steven Bair has written about Drug Resistance, Neoplasm.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.147 |
|
|
|
-
Bair SM, Mato A, Svoboda J. Immunotherapy for the Treatment of Hodgkin Lymphoma: An Evolving Paradigm. Clin Lymphoma Myeloma Leuk. 2018 06; 18(6):380-391.
Score: 0.104
-
Zelikson V, Gurumurthi A, Sawalha Y, Annunzio K, Saha A, Dong N, Qualls D, Amoozgar B, Kahl B, Baird J, Challa P, Huntington SF, Santos J, Bair S, Narkhede M, Li S, Frosch Z, Ho C, Smith SD, Winter A, Landsburg D, Furqan F, Hamadani M, Baird K, Romancik J, Alharthy H, Law J, Bojanini L, Advani R, Hu B, Johnson PC, Grover NS, Merril M, Crombie JL, Shafagati N, Sterling C, Nastoupil LJ, Epperla N, Ayers EC. Loncastuximab in high-risk and heavily pretreated relapsed/refractory diffuse large B-cell lymphoma: a realworld analysis from 21 US centers. Haematologica. 2025 Mar 01; 110(3):706-714.
Score: 0.042
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|